Alcohol use and burden for 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016

Carregando...
Imagem de Miniatura
Citações na Scopus
2012
Tipo de produção
article
Data de publicação
2018
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER SCIENCE INC
Autores
GRISWOLD, Max G.
FULLMAN, Nancy
HAWLEY, Caitlin
ARIAN, Nicholas
ZIMSEN, Stephanie R. M.
TYMESON, Hayley D.
VENKATESWARAN, Vidhya
TAPP, Austin Douglas
FOROUZANFAR, Mohammad H.
SALAMA, Joseph S.
Citação
LANCET, v.392, n.10152, p.1015-1035, 2018
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background Alcohol use is a leading risk factor for death and disability, but its overall association with health remains complex given the possible protective effects of moderate alcohol consumption on some conditions. With our comprehensive approach to health accounting within the Global Burden of Diseases, Injuries, and Risk Factors Study 2016, we generated improved estimates of alcohol use and alcohol-attributable deaths and disability-adjusted life-years (DALYs) for 195 locations from 1990 to 2016, for both sexes and for 5-year age groups between the ages of 15 years and 95 years and older. Methods Using 694 data sources of individual and population-level alcohol consumption, along with 592 prospective and retrospective studies on the risk of alcohol use, we produced estimates of the prevalence of current drinking, abstention, the distribution of alcohol consumption among current drinkers in standard drinks daily (defined as 10 g of pure ethyl alcohol), and alcohol-attributable deaths and DALYs. We made several methodological improvements compared with previous estimates: first, we adjusted alcohol sales estimates to take into account tourist and unrecorded consumption; second, we did a new meta-analysis of relative risks for 23 health outcomes associated with alcohol use; and third, we developed a new method to quantify the level of alcohol consumption that minimises the overall risk to individual health. Findings Globally, alcohol use was the seventh leading risk factor for both deaths and DALYs in 2016, accounting for 2.2% (95% uncertainty interval [UI] 1.5-3.0) of age-standardised female deaths and 6.8% (5.8-8.0) of age-standardised male deaths. Among the population aged 15-49 years, alcohol use was the leading risk factor globally in 2016, with 3.8% (95% UI 3.2-4-3) of female deaths and 12.2% (10.8-13-6) of male deaths attributable to alcohol use. For the population aged 15-49 years, female attributable DALYs were 2.3% (95% UI 2.0-2.6) and male attributable DALYs were 8.9% (7.8-9.9). The three leading causes of attributable deaths in this age group were tuberculosis (1.4% [95% UI 1. 0-1. 7] of total deaths), road injuries (1.2% [0.7-1.9]), and self-harm (1.1% [0.6-1.5]). For populations aged 50 years and older, cancers accounted for a large proportion of total alcohol-attributable deaths in 2016, constituting 27.1% (95% UI 21.2-33.3) of total alcohol-attributable female deaths and 18.9% (15.3-22.6) of male deaths. The level of alcohol consumption that minimised harm across health outcomes was zero (95% UI 0.0-0.8) standard drinks per week. Interpretation Alcohol use is a leading risk factor for global disease burden and causes substantial health loss. We found that the risk of all-cause mortality, and of cancers specifically, rises with increasing levels of consumption, and the level of consumption that minimises health loss is zero. These results suggest that alcohol control policies might need to be revised worldwide, refocusing on efforts to lower overall population-level consumption.
Palavras-chave
Referências
  1. Acland A, 2013, NUCLEIC ACIDS RES, V41, pD8, DOI 10.1093/nar/gks1189
  2. Britton A, 2017, ADDICTION, V112, P218, DOI 10.1111/add.13585
  3. Chikritzhs T, 2015, ADDICTION, V110, P726, DOI 10.1111/add.12828
  4. Degenhardt L, 2013, LANCET, V382, P1564, DOI 10.1016/S0140-6736(13)61530-5
  5. Di Castelnuovo A, 2006, ARCH INTERN MED, V166, P2437, DOI 10.1001/archinte.166.22.2437
  6. Fekjaer HO, 2013, ADDICTION, V108, P2051, DOI 10.1111/add.12104
  7. Fillmore KM, 2006, ADDICT RES THEORY, V14, P101, DOI 10.1080/16066350500497983
  8. Forouzanfar MH, 2015, LANCET, V386, P2287, DOI 10.1016/S0140-6736(15)00128-2
  9. Gakidou E, 2017, LANCET, V390, P1345, DOI 10.1016/S0140-6736(17)32366-8
  10. Gmel G, 2003, EUR J EPIDEMIOL, V18, P631, DOI 10.1023/A:1024805021504
  11. HILL AB, 1965, P ROY SOC MED, V58, P295
  12. Holman CDJ, 1996, MED J AUSTRALIA, V164, P141
  13. Holmes MV, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g4164
  14. Holst C, 2017, ADDICTION, V112, P1358, DOI 10.1111/add.13799
  15. Howard AA, 2004, ANN INTERN MED, V140, P211, DOI 10.7326/0003-4819-140-6-200403160-00011
  16. Institute for Health Metrics and Evaluation, GLOB BURD DIS STUD 2
  17. Karriker-Jaffe KJ, 2018, J STUD ALCOHOL DRUGS, V79, P239
  18. Knott CS, 2015, BMJ-BRIT MED J, V350, DOI [10.1136/bmj.h384, 10.1136/BMJ.h384]
  19. Lim SS, 2012, LANCET, V380, P2224, DOI 10.1016/S0140-6736(12)61766-8
  20. Lopez AD, 2006, GLOBAL BURDEN OF DISEASE AND RISK FACTORS, P1, DOI 10.1596/978-0-8213-6262-4
  21. Naimi TS, 2017, ADDICTION, V112, P207, DOI 10.1111/add.13451
  22. Naimi TS, 2005, AM J PREV MED, V28, P369, DOI 10.1016/j.amepre.2005.01.011
  23. Nelson DE, 2010, ADDICTION, V105, P1589, DOI 10.1111/j.1360-0443.2010.03007.x
  24. Rehm J, 2003, ADDICTION, V98, P1209, DOI 10.1046/j.1360-0443.2003.00467.x
  25. Rehm J, 2003, EUR ADDICT RES, V9, P157, DOI 10.1159/000072222
  26. Rehm J, 2010, POPUL HEALTH METR, V8, DOI 10.1186/1478-7954-8-3
  27. RONKSLEY PE, 2011, BMJ-BRIT MED J, V342, pd671, DOI 10.1136/BMJ.D671
  28. Schwarzinger M, 2018, LANCET PUBLIC HEALTH, V3, pE124, DOI 10.1016/S2468-2667(18)30022-7
  29. Stevens GA, 2016, LANCET, V388, pE19, DOI 10.1016/S0140-6736(16)30388-9
  30. Stockwell T, 2016, J STUD ALCOHOL DRUGS, V77, P185, DOI 10.15288/jsad.2016.77.185
  31. Topiwala A, 2018, EVID-BASED MENT HEAL, V21, P12, DOI 10.1136/eb-2017-102820
  32. WHO, 2014, GLOBAL STATUS REPORT ON VIOLENCE PREVENTION 2014, P1
  33. WHO, 2017, TACKL NCDS BEST BUYS